Bacterial type I signal peptidase inhibitors-Optimized hits from natureShow others and affiliations
2022 (English)In: European Journal of Medicinal Chemistry, ISSN 0223-5234, E-ISSN 1768-3254, Vol. 238, article id 114490Article in journal (Refereed) Published
Abstract [en]
The ever-increasing number of bacteria resistant to the currently available antibacterial agents is a great medical problem today, and new antibiotics with novel mechanisms of action are urgently needed. Among the validated antibacterial drug targets against which new classes of antibiotics might be directed is bacterial type I signal peptidase (SPase I), an essential part of the Tat and Sec secretory systems. SPase I is responsible for the hydrolysis of the N-terminal signal peptides from proteins secreted across the cytoplasmic membrane and plays a key role in bacterial viability and virulence. This review focuses on the antibacterial activity of natural and synthetic SPase I inhibitors reported to date, namely beta-lactams, lipopeptides, and arylomycins, but also an example of SPase I activator was presented.
Place, publisher, year, edition, pages
Elsevier BV Elsevier, 2022. Vol. 238, article id 114490
Keywords [en]
Antibiotics, Bacterial resistance, Lipopeptides, Arylomycin, ?-lactam, Bacterial type I signal Peptidase, SPase I
National Category
Medicinal Chemistry
Identifiers
URN: urn:nbn:se:uu:diva-479892DOI: 10.1016/j.ejmech.2022.114490ISI: 000810543200006PubMedID: 35660251OAI: oai:DiVA.org:uu-479892DiVA, id: diva2:1680782
2022-07-052022-07-052024-01-15Bibliographically approved